Akari Therapeutics, Plc announced on May 1, 2025, the appointment of Mark F. Kubik as Head of Business Development - Oncology. Mr. Kubik brings over 25 years of experience in the oncology industry, with a successful track record in establishing transformative transactions.
His expertise includes Antibody-Drug Conjugates (ADCs) and antibody therapies, ranging from early discovery to preclinical and clinical stages. Mr. Kubik has held leadership positions at companies such as SeaGen (now Pfizer), Abgenix (now Amgen), MacroGenics, and OncoImmune.
Abizer Gaslightwala, President and CEO of Akari, stated that Mr. Kubik will lead the company's business development activities for its novel ADC platform and lead asset, AKTX-101, including collaboration and partnership efforts. This appointment aims to maximize opportunities for non-dilutive capital and position Akari as a key player in the ADC space.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.